Coronary/Structural Heart

New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions

MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) — Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies. Study results were presented at the Society of Cardiovascular Computed Tomography (SCCT) Conference in […]

Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America

CARLSBAD, Calif., July 28, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. Ionis previously granted AstraZeneca exclusive rights to commercialize eplontersen in all other countries outside the U.S. Ionis and AstraZeneca will continue to jointly […]

FDA Clears Numares Health Cardiovascular Diagnostic Test and Core Technology Platform

THE WOODLANDS, Texas and REGENSBURG, Germany, July 25, 2023 /PRNewswire/ — The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease. Currently, Numares is the only company in the US selling an FDA-cleared […]

Cleerly and Cenegenics Partner to Offer Heart Disease Prevention Technology as Part of Performance Health Age Management Portfolio

DENVER – JULY 18, 2023 — Cleerly, the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease, today announced a partnership with Cenegenics, a leading performance health age management platform dedicated to helping people achieve their peak cognitive, physical and metabolic health. Through […]

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP® Cell Therapy Heart […]

Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

Basel, 24 July 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a new partnership with Alnylam to develop and commercialise zilebesiran, an investigational RNAi therapeutic currently in Phase 2 for the treatment of hypertension. Hypertension affects more than 1.2 billion adults worldwide and is the main, independent, preventable […]

HeartFlow, Inc. to Announce New Data on Diagnosing and Managing Coronary Artery Disease at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting

MOUNTAIN VIEW, Calif., July 24, 2023 (GLOBE NEWSWIRE) — HeartFlow, Inc., the only non-invasive precision coronary care solution to provide both anatomic and physiologic insights, today announced that new data on HeartFlow Plaque Analysis and its RoadMapTM Analysis will be presented at the 2023 Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific […]

Reliq Health Technologies, Inc. Announces Successful AI Deployments with Key Clients

HAMILTON, Ontario, July 21, 2023 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, is pleased to announce that it has successfully deployed integrated Artificial Intelligence […]

Viva Biotech’s Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs

WATERTOWN, Mass., July 20, 2023 /PRNewswire/ — Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular diseases. Riparian today announced it has entered into an exclusive license agreement and research agreement with Pfizer. In exchange for exclusive rights to a Riparian preclinical program, […]